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M A J O R A R T I C L E
Clarithromycin Versus Azithromycin
in the Treatment of Mediterranean Spotted
Fever in Children: A Randomized
Controlled Trial
Antonio Cascio,1,a Claudia Colomba,1 Spinello Antinori,1 David L. Paterson,2 and Lucina Titone1
1Istituto di Patologia Infettiva e Virologia, Ospedale “G. Di Cristina,” Universita` di Palermo, and 2Infectious Diseases Section,
University of Pittsburgh Medical Center Overseas, Palermo, Italy
We conducted an open-label randomized controlled trial to compare the efficacy and safety of clarithromycin
(15/mg/kg/day in 2 divided doses for 7 days) with those of azithromycin (10 mg/kg/day in 1 dose for 3 days)
in the treatment of children with Mediterranean spotted fever. Until now, there has not been a gold-standard
therapy for this rickettsial disease in children. Eighty-seven children were randomized to receive 1 of the 2
drugs. The mean time to defervescence ( standard deviation) was h in the clarithromycin group46.2 36.4
and h in the azithromycin group. These differences were not statistically significant and both39.3 31.3
drugs were equally well-tolerated. Clarithromycin and azithromycin could be acceptable therapeutic alternatives
to chloramphenicol and tetracyclines for children aged 8 years with Mediterranean spotted fever. Azithro-
mycin, because it has a long half-life, offers the advantages of administration in a single daily dose and a
shorter duration of therapy, which could increase compliance in children.
Mediterranean spotted fever (MSF) is caused by Rick-
ettsia conorii, which is transmitted by the dog tick Rhipi-
cephalus sanguineus. It is an acute infectious disease
typically characterized by fever, skin rash, and a black
eschar (tache noire) at the site of tick bite . Every year,
300 cases are notified (mainly from June through Sep-
tember) on the Italian island of Sicily [1–3]. Interest-
ingly, the number of cases in Italy and elsewhere appears
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to have increased during the past 20 years [4–7]. Spo-
radic cases have been diagnosed in travelers in other
countries as well, and, in North America, MSF is the
most frequently imported type of rickettsiosis [8–10].
In the Western Hemisphere, Rocky Mountain spot-
ted fever (RMSF), which is caused by Rickettsia rick-
ettsii, can be a severe disease, but MSF is generally
milder [11]. Historical studies have shown that MSF
can lead to 10-14 days of fever if not treated, but it is
rarely fatal in children [11]. Tetracyclines or chloram-
phenicol is considered standard treatment for MSF
[12]. However, both these drugs can cause significant
adverse effects, especially in children. Tetracyclines can
cause staining of the teeth and bone toxicity [13]. Nev-
ertheless, doxycycline is the treatment of choice for
children aged 8 years who have RMSF [14].
Chloramphenicol can have severe adverse effects,
such as gray syndrome (“gray-baby syndrome”), aplas-
tic anemia, and acute hemolytic anemia, in patients
with the Mediterranean form of glucose-6-phosphate
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Table 1. Diagnostic scoring system for Mediterranean spot-
ted fever, as described in Raoult et al. [26].
Diagnostic criteria Points
Epidemiologic
Residence or recent travel in area of endemicity 2
Onset during May–September 2




Maculopapular or purpuric eruption 5
2 of 3 criteria 3
All 3 criteria 5
Nonspecific biological
Platelet count of !150  109 cells/L 1
Liver enzyme level (AST or ALT) of 150 IU/L 1
Bacteriological
Detection of Rickettsia conorii in skin biopsy
specimen by use of IFA 25
Isolation of R. conorii from blood 25
Serological (determined by use of IFA)
1 Sample with total Ig 1:128 5
1 Sample with IgG 1:128 and IgM 1:64 10
2 Samples with 4-fold titer elevation within 2 weeks 20
NOTE. A total of 125 points is consistent with a presumptive diagnosis
of Mediterranean spotted fever. ALT, alanine transaminase; AST, aspartate
transaminase; IFA, immunofluorescence assay; tache noire, black eschar
that appears at the site of a tick bite.
dehydrogenase (G6PD) deficiency [15–17].
The macrolides—clarithromycin, azithromycin, roxithro-
mycin, and josamycin—do not have such adverse effects and
seem to be effective in vitro; for this reason, they have emerged
as a potential alternative therapy [18–25]. Members of the ge-
nus Rickettsia are obligate intracellular bacteria, and the main
feature of MSF is generalized vasculitis and localization of R.
conorii in endothelial cells [3]. Effective intracellular concen-
trations of antimicrobials are therefore considered the sine qua
non for a successful treatment for this disease.
The aim of this study was to compare the efficacy and safety
of azithromycin with those of clarithromycin for the treatment
of children with MSF. Azithromycin achieves higher intracel-
lular concentrations than do the other macrolides (including
clarithromycin), and this ability may contribute to its efficacy
in the treatment of infections caused by intracellular organisms,
such as rickettsial infections. Furthermore, the long half-life of
azithromycin offers the advantage that the drug can be ad-
ministered in a single daily dose, which could increase com-
pliance in children.
PATIENTS AND METHODS
All patients who were admitted to the “G. Di Cristina” chil-
dren’s hospital in Palermo, Italy, from June 1999 through Sep-
tember 2000, and had clinically suspected MSF (i.e., findings
of fever, nonconfluent maculopapular rash, and tache noire
that occurred during June–September) were evaluated for pos-
sible inclusion in the study. At admission, a complete physical
examination was performed, the typical signs of MSF were
sought, and a peripheral venous blood sample was obtained
for performance of a complete blood cell count and determi-
nation of the erythrocyte sedimentation rate, C-reactive protein
level, and liver function. An indirect immunofluorescence assay
for R. conorii was performed with use of a commercial kit
(Rickettsia conorii-Spot; bioMe´rieux). Informed consent to par-
ticipate in the study was sought from parents of the patients.
Exclusion criteria were as follows: age 114 years; lack of
parental informed consent; a history of allergy to the drugs
being studied; presence of severe disease, defined by neurolog-
ical signs (stiff neck or seizures), hemorrhagic manifestations,
or sepsis (any combination of hypotension, tachycardia, and
tachypnea with values greater than or less than the mean
standard deviations for the age]); alanine aminotransferase2
concentration 1250 U/L; creatinine concentration 11.5 mg/dL;
and a history of treatment with antibiotics potentially active
against Rickettsia species (e.g., macrolides, tetracyclines, chlo-
ramphenicol, or quinolones) in the 7 days before hospital-
ization.
After informed consent was obtained, children with clinically
suspected MSF and without exclusion criteria were randomly
assigned to receive either clarithromycin (15/mg/kg/day in 2
divided doses for 7 days) or azithromycin (10 mg/kg once daily
for 3 days). Simple randomization was performed according
to a list of computer-generated random numbers with use of
Epi-Info software (Centers for Diseases Control and Prevention
[CDC]). Odd numbers indicated one treatment, even numbers
the other. The randomization list was covered with opaque
adhesive paper. The final study population was the group of
enrolled children who had a confirmed diagnosis of MSF. Con-
firmation was defined as an MFS diagnostic score of 125, ac-
cording to the scoring system described in Raoult et al. [26]
(table 1).
Clinical response to antibiotic treatment was evaluated on
the basis of the pattern of body temperature data and the im-
provement in the clinical signs and symptoms of the disease.
The time to defervescence was defined as the time from the
beginning of antibiotic therapy to the first achievement of per-
sistent defervescence (i.e., an axillary body temperature of
37C for at least 3 consecutive days) [27]. Body temperature
was measured every 6 h by nursing personnel who were not
involved in the study. Nurses were instructed to administer
acetaminophen (10 mg/kg) every time a patient’s temperature
was 138.5C, although not for 14 times per day.
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Male sex, n/N (%) 28/42 (66.6) 26/45 (57.7%) NS
Age, years 5 (1–14) 6 (0.5–13) NS
Fever, n/N (%) 42/42 (100) 45/45 (100) NS
Duration of fever before
treatment, days 3 (0–8) 3 (0–8) NS
Duration of exanthema before
treatment, days 1 (0–7) 1 (0–6) NS
Exanthema, n/N (%) 42/42 (100) 45/45 (100) NS
Tache noire, n/N (%) 37/42 (88) 33/45 (73.3) .08
Arthralgia, n/N (%) 15/42 (35.7) 18/45 (40) NS
Erythrocyte sedimentation
rate, mm/h 26 (12–57) 26 (9–101) .17
AST level, IU/L 38.5 (20–137) 38 (20–98) .19
ALT level, IU/L 28.5 (7–212) 24 (11–46) .19
Platelet count,  103 cells/mL 199 (68–387) 207.5 (84–353) NS
WBC count,  103 cells/mL 6.3 (2.4–35) 6.5 (2.7–22.8) NS
CRP level, mg/dL 2.3 (0.4–18) 2.7 (0.4–6) NS
NOTE. Data are median value (range) unless indicated otherwise. ALT,
alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein;
NS, not significant. There were no significant differences between the 2 groups
in presenting characteristics (as determined by Student’s t test or Mann-Whit-
ney U test and x2 test).
Treatment safety and tolerability were judged on the basis of
the incidence and severity of the drug-related adverse effects
observed in the 2 groups. Immediately after therapy ended
(after 3 or 7 days), liver function tests were performed and
complete blood cell count and erythrocyte sedimentation rate
were determined; serological testing was done after days.30 3
Clinical examination was performed again after days15 2
and days, in order to exclude relapses.30 3
The analysis of the data was done with Statistica (StatSoft)
and Epi-Info (CDC) software. Contingency data were analyzed
by use of the 2-tailed x2 test or Fisher’s exact test, continuous
data were analyzed by use of the Student’s t test, and non-
normally distributed data were analyzed by use of the Mann-
Whitney U test. The Pearson correlation coefficient was com-
puted to verify the existence of correlations between variables.
A P value !.05 in a 2-sided test was considered significant for
all analyses. The clinical protocol was approved by the ethical
committee and review board of the G. Di Cristina hospital, and
the guidelines of the G. Di Cristina hospital were followed in
the conduct of the clinical research.
RESULTS
A total of 105 patients with suspected MSF were admitted to
hospital during the study period. Eight patients who had re-
ceived drugs potentially active against Rickettsia species in the
7 days before hospitalization were excluded from randomiza-
tion. Ninety-seven patients were randomized to receive the
study drugs. Eighty-seven of these 97 patients had a diagnostic
score of 125 and were considered the final study population;
45 were assigned to the clarithromycin group and 42 to the
azithromycin group. The baseline characteristics of these pa-
tients are summarized in table 2; the 2 treatment groups were
similar with respect to major demographic variables and char-
acteristics of MSF at the time of study enrollment. There were
no statistically significant differences between the 2 groups with
respect to hematological, chemical, and inflammatory param-
eters (table 2).
In all patients, fever disappeared in 7 days after the start
of therapy. In the clarithromycin group, defervescence was
achieved after a mean (SD) of h (median, 32 h;46.2 36.4
range, 6–168 h); in the azithromycin group, defervescence was
achieved after a mean (SD) of h (median, 28 h;39.3 31.3
range, 6–144 h). These differences were not statistically signif-
icant ( ). Fever that persisted for 15 days was observedPp .34
in 2 patients (1 in each treatment arm); chloramphenicol (12.5
mg/kg q6h) was administered to these 2 patients, who became
afebrile 48 h later. The patient in the azithromycin group had
undergone splenectomy 2 years previously because of b-thal-
assemia major (Cooley’s anemia). There were no significant
differences between the 2 groups with respect to the use of
acetaminophen (which all patients received).
The median duration of exanthema after the beginning of
therapy was 3 days (range, 1–5 days) in both groups. At ad-
mission, leukopenia (!5000 cells/mL) and thrombocytopenia
(!100,000 cells/mL) were observed in 14 and 2 patients in the
clarithromycin group, respectively, and in 8 and 3 patients in
the azithromycin group, respectively. Both leukopenia and
thrombocytopenia normalized (to 15000/mL and 1100,000/mL,
respectively) in the 2 groups after a mean (SD) of 6 1
days. No relapses were observed during follow-up. For all the
patients, a 4-fold increase of antibody titer to R. conorii was
observed at days after hospitalization.30 3
Clarithromycin and azithromycin were equally well-toler-
ated, and no major side effects were observed. Two patients
treated with clarithromycin developed vomiting, 1 developed
diarrhea, and 1 developed abdominal pain; only 1 patient
treated with azithromycin complained of abdominal pain. None
of these minor side effects required discontinuation of the drug
treatment. All analyses were also performed for the 10 patients
that did not have a diagnostic score of 125. No statistically
significant differences were observed (data not shown).
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Table 3. Summary of the findings of 5 randomized clinical trials of macrolide treatment for Mediterranean spotted fever in
children.
Reference Drugs and regimens studied
No. of
patients Findings
[27] Clarithromycin, 7 days (7.5 mg/kg b.i.d.) vs.
chloramphenicol, 7 days (12.5 mg/kg q.i.d.)
46 More-rapid disappearance of fever in the group
treated with clarithromycin
[29] Erythromycin stearate, 10 days (12.5 mg/kg
q.i.d) vs. tetracycline hydrochloride, 10 days
(10 mg/kg q.i.d.)
81 More-rapid disappearance of fever and symptoms
in the group treated with tetracycline
[30] Azithromycin, 3 days (10 mg/kg once a day) vs.
doxycycline, 5 days (5 mg/kg once a day)
30 No statistically significant differences in time to
defervescence
[31] Doxycycline, 1 day (2.5 mg/kg b.i.d.) vs.
josamycin, 5 days (25 mg/kg b.i.d.)
32 No statistically significant differences in time to
defervescence
Present report Azithromycin, 3 days (10 mg/kg once a day) vs.
clarithromycin, 7 days (7.5 mg/kg b.i.d.)
87 No statistically significant differences in time to
defervescence
DISCUSSION
Mediterranean spotted fever is an acute tickborne disease that
is caused by R. conorii and usually has a benign course in
children. Nevertheless, clinical manifestations are typically se-
vere; they include abrupt onset of high fever, intense headache
and malaise, myalgia, and maculopapular skin rash. If left un-
treated, MSF has a duration of 10–15 days [11].
Because R. conorii causes an intracytoplasmic infection, it is
necessary that the antibiotics administered achieve good
membrane penetration and concentrate within the cytoplasm.
These criteria are met by tetracyclines and chloramphenicol,
but neither drug should be routinely used in children, and less-
toxic alternatives are needed. In contrast, the macrolides achieve
high intracellular concentrations. Intracellular half-life varies
considerably from one macrolide to another, but it is partic-
ularly long for azithromycin. This property, together with the
ability of azithromycin to achieve high intracellular concentra-
tions, suggests that it may be possible to reduce doses, to pro-
long the interval between administration of doses, and to
shorten the duration of administration, relative to other drug
treatments. Therefore, it may be an ideal drug for the treatment
of MSF in children [28].
We previously conducted a randomized trial in which we
found that clarithromycin was significantly more effective than
chloramphenicol in the treatment of MSF in children [27]. In
the present study, we conducted a prospective open-label com-
parative randomized trial to compare the safety and efficacy of
clarithromycin versus those of azithromycin in the treatment
of MSF in children. We were not able to demonstrate significant
differences between the 2 treatment groups with respect to the
time to defervescence and to disappearance of other symptoms.
What are the weaknesses of our study? The study was not
double blinded, so we could not ensure that no bias occurred
in the observation of fever by nurses who knew which drug
the patient had received. However, the nurses who recorded
the body temperatures were not involved with the study in any
way, and intentional misrepresentation of fever seems unlikely
to have occurred. Although this was the largest randomized
trial of therapy of MSF ever performed, the sample size may
still have been insufficient to allow statistically significant dif-
ferences to be observed. With respect to the patients who were
not enrolled in the study because their clinical MSF diagnostic
score was 25, we could not exclude the possibility that they
actually had MSF. In fact, milder forms of MSF have been
described, especially in children [1]. In addition, the results of
serological testing are often negative at the beginning of the
disease, and, in our laboratory, we were not able to perform
isolation of R. conorii from blood samples or detection of the
organism in skin biopsy specimens. However, when we analyzed
the data for both our study groups and included the data for
the 10 patients who did not have a diagnostic score of 125,
our findings were not altered.
Four randomized clinical trials have been performed to com-
pare macrolides in the treatment of MSF in children [27, 29–31]
(table 3), but none of the studies have compared new ma-
crolides. In all these studies, the drugs were administered orally,
and the clinical response to the different antibiotic treatments
was evaluated on the basis of the pattern of body temperature
and the improvement of the clinical signs and symptoms of
the disease. Only 1 study [27] that compared the efficacy of
clarithromycin versus chloramphenicol obtained better (statis-
tically significant) results for the clarithromycin group. On the
other hand, only 1 of the other studies [29] showed that tet-
racycline hydrochloride is superior to erythromycin stearate.
However, erythromycin demonstrates in vitro activity against
R. conorii that is not as potent as that of newer macrolides,
such as clarithromycin [18–25].
Clarithromycin and azithromycin could be acceptable ther-
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apeutic alternatives to chloramphenicol and to tetracyclines for
children aged 8 years with MSF. Azithromycin, because it has
a long half-life, offers the advantages of administration in a
single daily dose and a shorter duration of therapy, which could
increase compliance in children. Further evaluation of ma-
crolides in patients with severe symptoms or serious illness
should be undertaken. Because these drugs have not been tested
as treatment for RMSF or other rickettsioses, their use for these
diseases is not recommended.
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